Idarucizumab is a monoclonal antibody fragment specifically designed to reverse the anticoagulant effects of dabigatran, a direct oral anticoagulant (DOAC) that inhibits thrombin. This reversal agent is crucial in situations where rapid anticoagulation reversal is necessary, such as in cases of severe bleeding or urgent surgical procedures. Idarucizumab binds to dabigatran with high affinity, effectively neutralizing its anticoagulant activity.
